Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF The SUMMIT Trial

Journal:

Journal of the American College of Cardiology

Published:

2025-07-22

DOI:

10.1016/j.jacc.2025.04.059

Affiliations:

7

Authors:

9

Go to article

Institutions	Authors	Share
Lilly, United States of America (USA)	4.142857	0.46
UVA Health System, United States of America (USA)	1.142857	0.13
Mayo Clinic, United States of America (USA)	1.142857	0.13
Imperial College London (ICL), United Kingdom (UK)	0.642857	0.07
Baylor University Medical Center at Dallas, United States of America (USA)	0.642857	0.07
Medical University of South Carolina (MUSC), United States of America (USA)	0.642857	0.07
Ralph H. Johnson VA Medical Center, United States of America (USA)	0.642857	0.07

Interested in Nutrition and Dietetics?